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Abstract
Introduction: Chemerin is a chemotactic peptide which directs leukocytes expressing the chemokine-like receptor
ChemR23 towards sites of inflammation. ChemR23 is a G protein-coupled receptor which binds several different
ligands, and it is also expressed by other cell types such as adipocytes. In addition to chemotaxis, recent reports
suggest that ChemR23 is capable of mediating either inflammatory or anti-inflammatory effects, depending on the
type of ligand it binds. In the present study, we aimed to clarify whether human chondrocytes express ChemR23
and chemerin, and whether chemerin/ChemR23 signalling could affect secretion of inflammatory mediators.
Methods: Tissue sections were taken from human knee joints and labelled with antibodies towards chemerin and
ChemR23. Chondrocytes from cartilage tissue were isolated, cultured and assessed for chemerin and ChemR23
expression by PCR and immunolabelling. Receptor activation and intracellular signalling were studied by
assessment of phosphorylated mitogen activated protein kinases (MAPKs) and phosphorylated Akt after stimulating
cells with recombinant chemerin
21-157. Biological effects of chemerin
21-157 were investigated by measuring
secretion of pro-inflammatory cytokines and metalloproteases in cell supernatants.
Results: Both serially cultured human articular chondrocytes and resident cells in native cartilage expressed
chemerin and ChemR23. Stimulating cells with chemerin
21-157 resulted in phosphorylation of p44/p42 MAPKs (ERK
1/2) and Akt (Ser 473). Also, significantly enhanced levels of the pro-inflammatory cytokines interleukin-6 (IL-6),
interleukin-8 (IL-8), tumour necrosis factor alpha (TNF-a), interleukin-1 beta (IL-1b), and the matrix metalloproteases
MMP-1, MMP-2, MMP-3, MMP-8 and MMP-13 were detected.
Conclusions: These results demonstrate that human chondrocytes express both the receptor ChemR23 and the
ligand chemerin. Chemerin
21-157 stimulation engaged signal-transduction pathways that further promoted
inflammatory signalling in chondrocytes, as judged by an enhanced secretion of cytokines and metalloproteases.
Taken together, the previously reported chemotaxis and the present findings suggest that the receptor and its
ligand may play pivotal roles in joint inflammation.
Introduction
Migration of leukocytes to sites of inflammation is a
hallmark of acute and chronic inflammation, and pre-
venting cell recruitment to inflamed tissues is evidently
a favourable strategy to reduce inflammation in arthritis
[1]. Recognizing that chondrocytes mediate inflamma-
tory signalling probably preceding leukocyte migration
as in arthritis, these cells appear to be key actors in the
early phase of the disease. Hence, it is importunate to
clarify whether these cells express receptors that med-
iate pro-inflammatory signalling.
Chemerin, also known as tazarotene-induced gene 2
(TIG2), is a chemotactic peptide that binds the G pro-
tein-coupled receptor ChemR23 [2]. Chemerin has been
detected at high levels in tissues such as psoriatic skin
[3], in synovial fluid from arthritic joints and in ascitic
fluids from human ovarian cancer and liver cancer [4,5].
Under normal physiological conditions, chemerin circu-
lates in an inactive form as prochemerin at nanomolar
concentrations, whereas activation is enabled by the
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end by proteases of the coagulation, fibrinolytic and
inflammatory cascades [6]. Prochemerin, which constitu-
tes 143 amino acids, is a precursor for several isoforms
of chemerin, including that in hemofiltrate and ascites
identified as the isoform chemerin
21-157 [1]. In addition
to chemotaxis, and by signalling through the receptor
ChemR23, the isoforms produced by serine proteases
possess pro-inflammatory properties, whereas those gen-
erated by cysteine proteases exert anti-inflammatory
activities [1,7]. Accordingly, prochemerin appears to
mediate dual effects, depending on the type of chemerin
isoform produced.
The receptor ChemR23, also known as chemokine-like
receptor 1 (CMKLR1), is expressed primarily by profes-
sional antigen-presenting cells such as dendritic cells
(DCs) [5], natural killer cells and macrophages [8].
Hence, it is a leukocyte chemoattractant receptor which
directs the migration of these cells to sites of inflamma-
tion. Neutrophils, the predominant leukocytes present
during early acute inflammation, are capable of promot-
ing maturation of prochemerin to chemerin, thus sug-
gesting that the chemerin/ChemR23 signalling system
may serve as a bridge between innate and adaptive
immunity [1], as shown by the fact that ChemR23 is
expressed by both myeloid DCs and plasmacytoid DCs,
subsequently promoting adaptive immunity [9].
There is compelling evidence of beneficial effects of
dietary supplements of eicosapentaenoic acid (EPA) in a
wide range of human inflammatory conditions including
arthritis [10-12]. The mechanisms explaining the benefi-
cial effects of EPA is still debated, and the primary the-
ory is that EPA interferes with the oxidation of
aracidonic acid (AA), by competitive inhibition [10]. It
has also been suggested that 15-lipoxygenase products
of EPA can affect the transcription factor NF-B, pre-
venting the activation of inflammatory genes [13,14].
One interesting finding is that ChemR23 binds the
endogenous lipid mediator derived from EPA, resolvin
E1 (RvE1), that in leukocytes leads to anti-inflammatory
signalling and promotion of resolution [13].
I nt h ep r e s e n ts t u d yw ea i m e dt oc l a r i f yw h e t h e r
human articular chondrocytes express ChemR23 and
whether recombinant chemerin
21-157 could elicit inflam-
matory signalling in these cells. Moreover, cellular
expression of chemerin was investigated to unravel a
possible inflammatory circuit in joints which may be
exploited by lipidmediators derived from EPA to pro-
mote resolution.
Materials and methods
The experiments were performed in accordance with
The Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving
humans. Patients gave a written informed consent to
use biopsies for scientific purposes, and the project was
approved by The Regional Ethics Committee.
Acquisition of chondrocytes
Human articular chondrocytes from knee joints were
obtained from patients subjected to autologous chon-
drocyte transplantation (ACT) and from osteoarthritic
(OA) patients subjected to total knee arthroplasty. Biop-
sies from ACT patients were collected and prepared as
previously described [15], while biopsies from osteoar-
thritic joints were taken from areas macroscopically
judged as the healthiest part of the cartilage. In both
cases, cells were isolated and cultured as previously
described [16]. Briefly, cells were cultivated in growth
medium Dulbecco’s Modified Eagle’s Medium (DMEM)/
Ham’s F12 (Cat. No. F4815, VWR, Oslo, Norway) sup-
plemented with L-glutamine (Cat. No. K0302, VWR)
gentamicin (Cat. No. G-1397, Sigma Aldrich, St. Louis,
MO, USA) amphotericin B (Cat. No. A-2942, Sigma
Aldrich) and 10% fetal calf serum (FCS) (Cat. No.
N-4637, Sigma Aldrich). ACT cells were initially cul-
tured in autologous human serum until transplantation,
that is, three to four weeks, and thereafter cryopre-
served. Subsequent propagation was supported by 10%
FCS, whereas cells from osteoarthritic joints had growth
medium supplemented with 10% FCS only.
Biopsies of cartilage serving as healthy controls were
taken from patients subjected to surgery due to recon-
struction of the anterior cruciate ligament (ACL). These
patients were under the age of 35 and had no previous
clinical symptoms of arthritis. Tissue removed as part of
the surgical procedure was included in the study pro-
vided that it had no macroscopic signs of inflammation.
Reverse transcriptase polymerase chain reaction (RT-PCR)
Messenger RNA (mRNA) from cultivated chondrocytes
was extracted with Qiagen Direct mRNA kit (Merck
Eurolab, Oslo, Norway). cDNA was synthesised by using
SuperScript Preamplification System (Life Technologies
Ltd., Paisley, UK) and treated with 0.1 unit/L E. coli
RNase-inhibitor at 37°C for 20 minutes. PCR was per-
formed in a 50 μl reaction mixture containing cDNA
(derived from 0.5 μg mRNA), 150 nM of each primer,
master mix containing Taq polymerase, dNTPs, MgCl2
and buffer (5 Prime MasterMix, Cat. No. PRME2200100,
VWR, Oslo, Norway), and ultra pure distilled water (Cat.
No. 10977-035, Gibco, Invitrogen, Oslo, Norway). The
PCR was performed at 94°C for 5 minutes (first denatura-
tion), 94°C for 30 sec (denaturation), 55°C for 30 sec
(annealing) and 72°C for 1 minute (extension) for a total
of 30 cycles with a 10-minute final extension at 72°C. All
reactions were run using a Perkin-Elmer GeneAmpPCR
system 2400 (Perkin-Elmer, Cambridge, UK).
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ChemR23 receptor were 5’-TGG TCT ACA GCA TCG
TC-3’ (sense) and 5’-ATG GCT GGG GTA GGA AGA
GT-3’ (antisense), and 917 base pair (bp) fragments
were expected [17]. We used two primer sets for human
prochemerin. The nucleotide sequences for primer set
one were 5’-GAA GAA ACC CGA GTG CAA AG-3’
(sense) and 5’-CTT GGA GAA GGC GAA CTG TC-3’
(antisense), and 229 bp fragments were expected [18].
T h en u c l e o t i d es e q u e n c e sf o rp r i m e rs e tt w ow e r e5 ’-
GGA GGA ATT TCA CAA GCA C-3’ (sense) and 5’-
GAA CTG TCC AGG GAA GTA GA-3’(antisense), and
361 bp fragments were expected [19].
To test the quality of mRNA, the presence of a house-
keeping gene transcript, adenine phosphoribosyltransfer-
ase (APRT), was assayed. 5’-CCC GAG GCT TCC TCT
TTG GC-3’ (sense), 5’-CTC CCT GCC CTT AAG CGA
GG-3’ (antisense), and contaminating DNA would gen-
erate a 800-bp fragment, whereas mRNA would gener-
ate a 300-bp fragment [16]. Genomic DNA was
obtained from DNA isolated from human leukocytes
and was used to assess possible contamination.
PCR products were analysed by the use of polyacryla-
mide gel (Novex TBE gel 6% Cat. No. EC6265BOX,
Invitrogen), stained with SYBR-safe DNA gel stain (Cat.
No. S33102, Invitrogen) and photographed under UV-
light using a G-BOX (Syngene, Cambridge, UK).
The sequences of the amplicons were confirmed using
BigDye
® Terminator v3.1 Cycle Sequencing Kit (Cat.
No. 4337455, Applied Biosystems, Foster City, CA,
USA). A total of 2 μl of each PCR product and 1 μMo f
each primer were processed according to the kit manual.
The cycle sequencing was performed on the GeneAmp
®
PCR Systems 9700 (Applied Biosystems) while the puri-
fication was done by capillary gel-electrophoresis on the
3130XL Genetic analyzer (Applied Biosystems).
Immunocytochemistry
To achieve the required amount of cells for in vitro
experiments, cells were passaged four times. The pheno-
type was assessed at the time of experiments by immu-
nolabelling for collagen type II and aggrecan, using the
primary antibodies: polyclonal rabbit anti-human col-
lagen II (Cat. No. ab34712, Abcam, Cambridge, UK) and
monoclonal mouse anti-human aggrecan (Cat. No.
ab3778, Abcam). The secondary antibodies used were:
polyclonal goat anti-rabbit IgG conjugated with Alexa
Fluor 594 (Cat. No. A21207, Invitrogen) and polyclonal
rabbit anti-mouse IgG conjugated with Alexa Fluor
488 (Cat. No. A11059, Invitrogen). Identification of
ChemR23 and chemerin was performed with the pri-
mary antibodies polyclonal rabbit anti-human ChemR23
antibody (Cat. No. ab13172, Abcam), and polyclonal
goat anti-human TIG-2 antibody (Cat. No. sc-47482,
Santa Cruz Biotechnology, Heidelberg, Germany). The
secondary antibodies used were: goat anti-rabbit IgG
conjugated with Alexa Fluor 488 (Cat. No. A11008, Invi-
trogen), and anti-goat IgG conjugated with Alexa Fluor
594 (Cat. No. A11058, Invitrogen). Chondrocyte cultures
were grown on fibronectin coated chamber slides (Cat.
No. 154534, Nunc, Roskilde, Denmark) for 24 h
(ChemR23 and chemerin labelling), and for seven days
(collagen II and aggrecan labelling). The cultures were
washed twice with phosphate buffered saline (PBS) and
fixed for 10 minutes in cold PBS containing 0.2 M
sucrose and 4% paraformaldehyde. After fixation, the
slides were blocked for one hour with PBS containing
1% bovine serum albumin (BSA). Thereafter, cell cul-
tures were incubated at 4°C overnight with the primary
antibodies. The slides were then washed three times in
PBS and incubated with secondary antibodies for one
hour in room temperature. Isotype control was used to
assess non-specific binding. The slides were mounted by
adding DAPI-fluoromount G (Cat. No. 0100-20, South-
ernBiotech, Birmingham, AL, USA) and examined in a
Zeiss axiophot photomicroscope (Carl Zeiss, Oberko-
chen, Germany).
Immunohistochemistry
Immunohistochemical studies were performed to inves-
tigate whether ChemR23 and chemerin were present in
native cartilage tissue. Biopsies were fixed in paraformal-
dehyde (4%) containing 0.2 M sucrose in PBS. After
48 h, the tissue was embedded in paraffin and sectioned
at 5 μm thickness onto poly-L-Lysine coated slides
(0.01%, Sigma Aldrich). Sections were deparaffinised by
xylene and graded alcohol washes and immersed in dis-
tilled water. Thereafter, sections were incubated in PBS
containing 1% BSA for 60 minutes followed by incuba-
tion with monoclonal mouse anti-human ChemR23
( C a t .N o .M A B 3 6 2 ,R & DS y s t e m s ,A b i n g d o n ,U K ) ,
diluted at 1:100 and incubated at 4°C overnight. After
rinsing in PBS, sections were incubated for 45 minutes
with secondary goat anti-mouse antibody conjugated
with horseradish peroxidase (SuperPicTure Polymer
detection kit, Invitrogen). For the detection of chemerin,
polyclonal goat anti-human TIG-2 (Cat. No. sc-47482,
Santa Cruz Biotechnology) was used, followed by an
Alexa Fluor 594 conjugated donkey anti-goat IgG
antibody (Cat. No. A11058, Invitrogen) for detection.
Sections were mounted by adding DAPI-fluoromount G
(Cat. No. 0100-20, SouthernBiotech). Matched isotype
antibodies were used as a control for non-specific back-
ground staining.
Western blotting
Intracellular signal transduction in chondrocytes stimu-
lated with chemerin was investigated by immunoblotting
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phosphorylated Akt (Ser473). To detect the phosphory-
lated MAPKs, a phospho-Erk1/2 pathway sampler kit
was used (Cat. No. 9911, Cell Signaling Technology,
Boston, MA, USA). Phospho-specific antibody towards
phospho-Akt (Ser473) was used to detect the ChemR23
mediated phosphorylation of Akt. Cell cultures were
treated with 10 nM recombinant human chemerin
21-157
(E. coli derived Glu 21 - Ser 157 with an N-terminal
Met, Cat. No. 2324-CM, R&D Systems) at various time
points. Cultures added medium only served as controls,
and a MEK1/2 inhibitor U0126 (Cat. No. 9900, Invitro-
gen) was added to some cultures one hour prior to
challenge with 10 nM chemerin. A number of 0.5 x10
6
cells were seeded per well in a six-multiwell plate (Cat.
No. 3046, Falcon, BD Biosciences, Trondheim, Norway)
and grown in a culture medium with 10% FCS for 24 h.
Subsequently, the cells were washed twice in PBS and
grown under reduced-serum conditions (0.1%) for 24 h.
Thereafter, cultures were washed twice and challenged
with 10 nM chemerin for 1 minute, 2.5 minutes, 5 min-
utes and 10 minutes. Cells were then harvested directly
in 150 μlS D S - b u f f e rc o n t a i n i n gN u P A G EL D Ss a m p l e
buffer (Cat. No. NP0007, Invitrogen), NuPAGE Redu-
cing agent (Cat. No. NP 0004, Invitrogen), phosphatase
inhibitor (Cat. No. 78420, Thermo Scientific, Chicago,
IL, USA), protease inhibitor (Cat. No. 04693124001,
Roche Applied Science, Basel, Switzerland), and distilled
water.
The amount of total protein was measured in each
lysate using Modular E 170 (Roche Diagnostics, Man-
nheim, Germany). The samples were heated to 100°C
for five minutes before an equal amount of protein
from each extract (390 μg) were loaded into different
wells. A total of 15 μl of a pre-stained protein marker
(Cat. No. 7720, Cell Signaling Technology) was added
to control the efficacy of the electrophoresis. Ten μlo f
a biotinylated protein ladder (Cat. No. 7727, Cell Sig-
naling Technology) to assess the molecular weights
(kDa) of proteins were also added. Proteins were sepa-
rated by electrophoresis in NuPAGE Mes SDS running
buffer (Cat. No. NP 0002, Invitrogen) at 200 V (con-
stant), using 100-125 mA per gel (NuPAGE 4-12%
BIS-tris gels, Cat. No. NP0323, Invitrogen) for 35 min.
Electroblotting was performed by electrontransfer onto
PVDF-membranes (Cat. No. LC2005, Invitrogen) in
NuPAGE transfer buffer (Cat. No. NP0006, Invitrogen)
with 10% methanol at 30 V (constant), using 170 mA
per gel transfer for 1 h. After electroblotting, the mem-
branes were blocked with 5% non-fat dry milk/0.1%
Tween 20 for 1 h at room temperature. Next, the
membranes were incubated with primary antibodies
overnight at 4 °C in 5% BSA/0.1% Tween 20. The
phospho-p44/42 (Thr202/Tyr204) antibody was used at
a 1:2000 dilution and the phospho-Akt (Ser473) anti-
body was diluted at 1:1000. To control for equal load-
ing amounts the membranes were incubated with
b-actin antibody (Cat. No. 4970, Cell Signaling Tech-
nology), dilution 1:1000. The membranes were then
washed and incubated with horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (Cat. No. 7074,
Cell Signaling Technology) a n dH R P - c o n j u g a t e da n t i -
biotin antibody (Cat. No. 7075, Cell Signaling Technol-
ogy) for 1 h at room temperature. Blots were detected
by adding substrate containing Lumiglo reagent and
peroxide (Cat. No. 7003, Cell Signaling Technology)
and developed with Fujifilm LAS-3000. A densito-
metric comparison between the protein bands was per-
formed using the GeneTools software (Syngene,
Cambridge, UK).
Cytokine and metalloprotease measurements
Chondrocyte cultures (0.5 × 10
6 cells/well) were incu-
bated for 24 h in medium supplemented with 10%
serum. Then, the cells were washed twice with PBS
and further incubated for 24 h and grown under
reduced-serum conditions (0.1%). The cultures were
then washed twice and one culture received medium
with 10 nM chemerin
21-157, another received medium
with 100 nM chemerin
21-157 a n dat h i r dw a sa d d e da
medium with vehicle only as control. The cultures
were incubated for 24 h before the medium superna-
tants were aliqouted and frozen in -70°C for later
analysis.
Cytokines were measured with a suspension array ana-
lytical platform (Bio-Plex 200, Bio-Rad, Hercules, CA,
USA). One ampoule of each supernatant was thawed on
ice, and the amount of total protein was measured in
each supernatant using a protein assay kit (Cat. No.
23227, Thermo Scientific, Rockford, IL, USA) before
levels of TNF-a,I L - 1 b,I L - 6a n dI L - 8w e r em e a s u r e d
using a 4-plex cytokine assay (Cat. No. X50053UVBS,
Bio-Rad). The samples were run in a 1:4 dilution in
duplicates.
Likewise, a multiplex MMP-assay was used to measure
the levels of the metalloproteases MMP-1, -2, -3, -7, -8,
-9, -12 and -13 (Cat. No. LMP000, R&D Systems) using
a Bio-Plex 200 analyser. The samples were run in a 1:4
dilution in duplicates.
Statistical analysis
Data were analysed using SPSS statistical software
version 16.0 (SPSS Inc., Chicago, IL, USA). Cytokines
and metalloproteases were examined for statistical sig-
nificance using the Wilcoxon signed-rank test. All data
are expressed as mean ± standard error of the mean
(SEM). A P-value less than 0.05 denoted the presence of
a statistically significant difference.
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Chondrocyte cultures
It has been demonstrated that chondrocytes gradually
lose their chondrogenic properties during serial passage
in monolayer [20,21]. To ensure a chondrogenic pheno-
type, cells were immunolabelled for aggrecan and col-
lagen type II after propagation in culture corresponding
to the time preceding in vitro experiments. As judged
by these parameters, the chondrogenic phenotype was
preserved (Figure 1).
ChemR23 and chemerin expression in human articular
chondrocytes
ChemR23 expression by RT-PCR
To clarify whether cultured human chondrocytes express
ChemR23, mRNA isolated from six different cell cultures
were analysed for ChemR23 transcripts by RT-PCR.
Figure 2a shows the ChemR23 transcripts in chondrocyte
cultures from two patients subjected to total knee arthro-
plasty due to severe osteoarthritis. The PCR products
detected by gel electrophoresis revealed that mRNA cor-
responding to the 917 bp transcript of the ChemR23 was
present (Figure 2a, Lanes 5 and 6). The APRT primers
were designed to give an 800 bp band in case of contami-
nation with genomic DNA, whereas the presence of a
3 0 0b pb a n dw o u l dc o r r e s p o n dt ot h em R N At r a n s c r i p t
for the APRT gene. As shown in the figure, genomic
DNA was not detected and both controls (Lanes 4 and 7)
were negative. The 917 bp transcript was identified in all
the tested cultures: three patients subjected to ACT due
to cartilage lesion and another three patients suffering
from severe osteoarthritis. Sequencing of the PCR pro-
ducts confirmed that they were transcripts for ChemR23
and APRT as judged by information obtained from the
GeneBank (NCBI) (Data not shown).
Chemerin expression by RT-PCR
To detect the presence of chemerin in chondrocytes,
mRNA isolated from two individual cell cultures was
analysed for prochemerin transcripts using two differ-
ent primer sets. Figure 2b shows prochemerin tran-
scripts in chondrocyte cultures from two patients
subjected to a total knee arthroplasty. The PCR
products detected by gel electrophoresis showed that
mRNA corresponding to the 229 bp transcript and
the 361 bp transcript of prochemerin was present in
both cultures (Figure 2b, Lanes 5, 6 and 9, 10). Geno-
mic DNA was not detected (Lanes 2 and 3) and all
controls (Lanes 4, 7 and 11) were negative. Sequen-
cing of the PCR products confirmed that they were
transcripts for chemerin and APRT as judged by
information obtained from the GeneBank (NCBI)
(Data not shown).
ChemR23 and chemerin expression in native cartilage
T h ep r e s e n c eo fC h e m R 2 3a n d chemerin proteins in
native cartilage was investigated by immunohistochemis-
try. Cartilage biopsies from two patients subjected to
ACT, four patients subjected to total knee arthroplasty
and three patients undergoing reconstruction of
ligaments were used. In all cases, cells residing in carti-
lage tissue were positively stained for both ChemR23
(Figure 3) and chemerin (Figure 4).
ChemR23 and chemerin expression in vitro
The presence of ChemR23 and chemerin was investi-
gated by immunocytochemistry of chondrocyte cultures
established from biopsies taken from seven individual
patients, three that were subjected to ACT, another
three subjected to total knee arthroplasty and one
undergoing reconstruction of a ligament. In all cases,
cells were positively stained for both ChemR23 and
chemerin (Figure 5)
Figure 1 Expression of collagen type II and aggrecan in cultured human articular chondrocytes. (a) Cells were labelled with polyclonal
rabbit anti-human collagen type II and secondary antibody conjugated with Alexa Fluor 594 (red). (b) Cells were labelled with monoclonal
mouse anti-human aggrecan and secondary antibody conjugated with Alexa Fluor 488 (green). The nuclei were visualized by Dapi dye (blue).
Isotype controls had no staining (not shown).
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21-157 stimulated the phosphorylation of MAPKs
and Akt
To assess whether intracellular signalling pathways were
engaged upon ligand-receptor binding, Western blots of
phospho-p44/42 MAPKs and phospho-Akt (Ser 473)
were performed. In separate experiments, cultured
chondrocytes from three patients subjected to total knee
arthroplasty were challenged with 10 nM chemerin
21-157
for 1 minute, 2.5 minutes, 5 minutes and 10 minutes,
respectively. Figure 6 shows that both p44/42 MAPKs
and Akt (Ser 473) were phosphorylated at specific resi-
dues. Challenging with chemerin
21-157 for 5 and 10 min-
utes showed a markedly increased phosphorylation of
the p44/42 MAPKs compared to the unstimulated
control, and inhibiting the MEK 1/2 pathway led to a
reduction of phosphorylated p44/42 MAPK including an
inhibition of the background phosphorylated p44/42
M A P K ,a ss h o w nb yan e g a t i v ed e n s i t yv a l u ec o m p a r e d
to the unstimulated control (Figure 6b).
Phosho-Akt levels increased from 1 minute up to 10
minutes after stimulation with chemerin
21-157 relative to
the control. These results demonstrate that chemerin
21-
157 binding to ChemR23 increases phosphorylation of
Akt which may induce activation of MEK1/2 and further
activate the MAPK pathway. Furthermore, addition of
the MEK 1/2 inhibitor did not affect the activation of
phospho-Akt after stimulation with chemerin
21-157 for
3.5 minutes.
Chemerin
21-157 promoted the secretion of pro-inflammatory
cytokines and MMPs
Based on the findings that ChemR23 expressed by chon-
drocytes transduced intracellular signalling in the pre-
sence of recombinant chemerin
21-157,f u r t h e rs t u d i e s
were conducted to investigate the biological significance.
Chondrocytes from three patients subjected to ACT,
and another three individuals subjected to total knee
arthroplasty, were in separate experiments challenged
with 10 nM or 100 nM chemerin
21-157 for 24 h, and
subsequently a panel of cytokines was measured in the
cell supernatants. The results (Figure 7) show an
increased concentration of TNF-a,I L - 1 b,I L - 6a n dI L - 8
as a result of chemerin stimulation in comparison to
unstimulated control cells (P < 0.05). The levels of IL-6
and IL-8 were markedly increased, whereas a rather
modest effect was observed in terms of altered levels of
IL-1b and TNF-a.
Joint inflammation is associated with deterioration of
the cartilage matrix requiring a clarification as to
whether chemerin
21-157 affects chondrocyte secretion of
matrix metalloproteases. Cell cultures from six indivi-
duals were arranged and challenged with 10 nM or 100
nM chemerin
21-157 for 24 h, and subsequently a panel of
eight different MMPs was measured in the supernatants.
Significantly (P < 0.05) elevated levels of MMP-1,
MMP-2, MMP-3, MMP-8, and MMP-13 were detected
(Figure 8). The metalloproteases MMP-7, MMP-9, and
MMP-12 could not be detected.
Discussion
Recent studies addressing ther o l eo fc h o n d r o c y t e si n
joint inflammation have revealed that these cells
secrete and bind a variety of cytokines and chemokines
[22-25] and that they possess immunoregulatory cap-
abilities [26]. The present study adds further informa-
tion to this issue by demonstrating that chondrocytes
in both native cartilage and cell culture express the
chemokine receptor ChemR23, a property primarily
ascribed to leukocytes.
Figure 2 Expression of ChemR23 and chemerin in cultured
human articular chondrocytes as detected by RT-PCR. (a) Lanes
2 and 3: RT-PCR with APRT primers and cDNA from two individual
cell cultures. Lane 4: APRT primers without cDNA. Lanes 5 and 6:
ChemR23 primers and cDNA from two individual cell cultures. Lane
7: ChemR23 primers without cDNA. Lane 8: APRT primers and
genomic DNA. (b) Lanes 2 and 3: RT-PCR with APRT primers and
cDNA from two individual cell cultures. Lane 4: APRT primers
without cDNA. Lanes 5 and 6: Prochemerin primer pair 1 and cDNA
from two individual cell cultures. Lane 7: Prochemerin primers
without cDNA. Lanes 9 and 10: Prochemerin primer pair 2 and
cDNA from two individual cell cultures. Lane 11: Prochemerin
primers without cDNA.
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21-157,
we demonstrated that chemerin/ChemR23 binding eli-
cits intracellular signalling leading to the phosphoryla-
tion of p44/42 MAPKs and Akt (Ser 473), both of
which are involved in central signal-transduction
pathways that convey inflammatory signalling
[27,28]. Hence, the cleavage product of prochemerin
chemerin
21-157 mediates pro-inflammatory signalling in
chondrocytes as judged by the observed promotion of
cytokine secretion.
The enzymes reported to generate chemerin
21-157
from prochemerin include the neutrophil serine pro-
teases cathepsin G and elastase [1]. This indicates that,
regardless of the source of prochemerin in joints, it
Figure 3 The presence of ChemR23 in sections of human articular cartilage. (a) Micrograph A (20X) shows positively (brown) stained
chondrocytes in tissue from one patient subjected to total knee arthroplasty. (b) Micrograph B shows an isotype control which was negative.
(c and d) Micrograph C (40X) and D (60X) shows positively stained chondrocytes from one patient undergoing reconstruction of ligament.
Figure 4 The presence of chemerin in sections of human articular cartilage. The micrograph (40X) shows positively (red) stained
chondrocytes in tissue from one patient undergoing ligament repair. Nuclei were visualized by Dapi dye (blue). Negative controls (isotype IgG)
had no red staining (not shown).
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Page 7 of 12can be cleaved by the enzymes produced by neutro-
phils into isoforms of chemerin that further promote
inflammation by recruiting leukocytes, and that pro-
mote chondrocyte secretion of pro-inflammatory cyto-
kines. Previous studies have reported that chemerin
21-
157 can be detected in arthritic synovial fluid [4,5] and
prochemerin from the circulation could likely be the
source. However, in the present study both cultured
chondrocytes and cells in native tissue were immuno-
positive towards chemerin. Taken together with the
finding that also mRNA for prochemerin was present
in chondrocytes, this strongly suggests that these cells
produce prochemerin that may serve as substrate for
neutrophil-derived serine proteases to generate che-
merin
21-157. Hence, resident chondrocytes secrete a
chemokine precursor that, after enzymatic cleavage by
enzymes secreted by neutrophils, further may recruit
leukocytes expressing the ChemR23 receptor. In addi-
tion, the cleavage product chemerin
21-157 can bind the
ChemR23 receptor expressed by chondrocytes which
promote their secretion of pro-inflammatory cytokines
and MMPs.
Figure 5 The presence of ChemR23 and chemerin in cultured human articular chondrocytes. (a) Cells were labelled with polyclonal rabbit
anti-human ChemR23 and secondary antibody conjugated with Alexa Fluor 488 (green). (b) Cells were labelled with polyclonal goat anti-human
TIG-2 (chemerin) and secondary antibody conjugated with Alexa Fluor 594 (red). Nuclei were visualized by Dapi dye (blue). Isotype controls had
no staining (not shown).
Figure 6 Western blot of phosphorylated p44/42 MAPKs (Thr202/Tyr204) and phosphorylated Akt (Ser 473). (a) Cultured chondrocytes
were challenged with 10 nM chemerin
21-157 for 1, 2.5, 5 and 10 minutes. Lane 1 represents the control where no chemerin was added and
Lane 6 represents the sample extract where the MEK 1/2 kinase inhibitor U0126 was added 1 h prior to a 3.5 minutes chemerin
21-157 challenge.
(b) The density of each band was normalized to b-actin, the graphs shows the increase in density relative to unstimulated control.
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Page 8 of 12A marked elevation of IL-8 and IL-6 was observed as
a result of chemerin
21-157 stimulation, whereas TNF-a
and IL-1b were modestly altered. Nevertheless, despite
low levels these may be sufficient to orchestrate an
inflammatory process due to their strong synergistic
effects, even at low concentrations [29]. In contrast,
there is a rather indisputably strong association between
the content of TNF-a in synovial fluid and disease activ-
ity such as in rheumatoid arthritis [30]. In our study, the
sole cytokine source was the chondrocytes, unlike the
situation occurring in a diseased joint where leukocytes
are also present. Yet according to previous reports, the
production of IL-6, IL-8 and MMPs in chondrocytes is
assigned to the action of TNF-a and IL-1b [25,31-34].
However, chemerin
21-157 may have induced an immedi-
ate release of TNF-a and IL-1b followed by internaliza-
tion and degradation, whereas IL-6, IL-8 and MMPs rely
on the autocrine action of TNF-a and IL-1b as reflected
at the time of measurement.
IL-8 exerts a potent chemotactic activity towards neu-
trophils [35], whereby it has a decisive role in the initial
stages of inflammation. Even so, the present study indi-
cates that chemerin may be a prerequisite for an aug-
mented secretion of IL-8. Consequently, chemerin/
Figure 7 Cytokine levels in supernatants from human articular chondrocytes stimulated with recombinant human chemerin
21-157. Cell
supernatants were assessed for cytokine contents after 24 h of stimulation with 10 nM or 100 nM recombinant chemerin
21-157. The levels of
TNF-a (a), IL-1b (b), IL-6 (c), and IL-8 (d) are shown as mean ± standard error of the mean. Results are from six separate experiments analyzed in
duplicates. Concentration is given relative to amount of protein (μg/ml). *P < 0.05, stimulated versus unstimulated.
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Page 9 of 12Figure 8 MMP levels in supernatants from human articular chondrocytes stimulated with recombinant human chemerin
21-157.C e l l
supernatants were assessed for content of MMPs after 24 h of stimulation with 10 nM or 100 nM recombinant chemerin
21-157. The levels of
MMP-1 (a), MMP-2 (b), MMP-3 (c), MMP-8 (d), and MMP-13 (e) are shown as mean ± standard error of the mean values. Results are from six
separate experiments analyzed in duplicates. Concentration is given relative to amount of protein (μg/ml). *P < 0.05, stimulated versus
unstimulated.
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Page 10 of 12ChemR23 could serve as a central link for the initiation
and maintenance of inflammation in joints.
It has previously been described that chondrocytes
produce IL-6 in response to physiologic and inflamma-
tory stimuli, and that IL-6 may serve as a mediator
coordinating responses to cartilage injury [32]. Since
IL-6 modulates the growth and differentiation of B- and
T-lymphocytes [36,37], our findings propose that
chemerin/ChemR23 signalling may contribute to the
activation of B- and T-cells leading to engagement of
adaptive immunity and further maturation of inflamma-
tion in joints.
MMP-2, MMP-3 and MMP-13 cleave the most abun-
dant proteoglycan in cartilage, aggrecan, at the Asn
373-
Phe
342 bond, and the resulting major fragment can be
detected in the synovial fluid from patients with various
arthritic diseases [38]. It has previously been reported
that these MMPs are produced by chondrocytes in vitro
[39-43]. The present results showed that chemerin
21-157
stimulation significantly increased secretion of MMP-1,
MMP-2, MMP-3, MMP-8 and MMP-13. This indicates
that chemerin
21-157 promotes secretion of enzymes that
digest the extracellular matrix, leading to deterioration
of cartilage tissue.
It was not our aim to compare the effect of che-
merin
21-157 on chondrocytes from healthy and diseased
joints, it appeared, however, that cells from the health-
iest donors (ACT) secreted lower amounts of cytokines
than OA cells. Using 100 nM chemerin
21-157, the ele-
vated secretion of IL-8 compared to unstimulated con-
trol was markedly lower (8 pg/ml) for ACT cells
compared to OA cells (25 pg/ml). This warrants a
further investigation of the effect of chemerin on chon-
drocytes in diseased and healthy stages.
Conclusions
We demonstrate that human articular chondrocytes
express the chemoattractant receptor ChemR23 and its
ligand chemerin. The latter being a chemokine that directs
migration of ChemR23
+ leukocytes. In chondrocytes, the
isoform chemerin
21-157 activates the intracellular signalling
cascades MAPKs and Akt, followed by an enhanced secre-
tion of pro-inflammatory cytokines and MMPs. This
implies that chemerin/ChemR23 signalling in chondrocytes
is capable of recruiting leukocytes to inflamed joints, and
that this signalling also can mediate cartilage deterioration.
In view of the inflammatory properties of chemerin/
ChemR23, this study reveals a molecular signalling
mechanism which may be targeted by appropriate inhibi-
tors to reduce joint inflammation and cartilage degradation.
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